Galilei Biosciences is a Cambridge-based early-stage company developing mammalian protein activators to tackle cancer development. The company targets a central regulator of DNA damage repair, as well as glucose and lipid metabolism, driving metabolic health and human longevity, thereby helping healthcare providers treat developmental diseases, metabolic diseases, and cancer.